Neurocrine Biosciences Inc vs T-Mobile Us Inc — how do they compare? Neurocrine Biosciences Inc trades at $179.88 (market cap $17.40B), while T-Mobile Us Inc trades at $190.5 (market cap $211.72B). The key difference: T-Mobile Us Inc is far larger — about 12.2× Neurocrine Biosciences Inc's market cap, and T-Mobile Us Inc pays a 2.09% dividend while Neurocrine Biosciences Inc pays none. Which is the better fit depends on your goals.
| NBIX | TMUS | |
|---|---|---|
Market Cap | $17.40B | $211.72B |
Sector | Health | Media |
52-Week High | $180.55 | $259.01 |
52-Week Low | $123.10 | $167.65 |
Enterprise Value | $16.49B | $329.42B |
Dividend Yield | — | 2.09% |
Trailing returns across standard periods
Latest headlines on both assets
Neurocrine Biosciences, Inc. is a biopharmaceutical company focused on discovering, developing, and commercializing innovative treatments for neurological, endocrine, and psychiatric disorders. The company's portfolio targets conditions such as tardive dyskinesia, endometriosis, and Parkinson's disease. NBIX leverages its expertise in neurobiology and small-molecule drug development to address diseases with significant unmet medical needs.
Read more on NBIX →Deutsche Telekom merged its T-Mobile USA unit with prepaid specialist MetroPCS in 2013, creating T-Mobile Us. Following the merger, the firm provided nationwide service in major markets but spottier coverage elsewhere. T-Mobile spent aggressively on low-frequency spectrum, well suited to broad coverage, and has substantially expanded its geographic footprint. This expansion, coupled with aggressive marketing and innovative offerings, produced rapid customer growth. With the Sprint acquisition, the firm's scale now roughly matches its larger rivals: T-Mobile now serves 71 million postpaid and 21 million prepaid phone customers, equal to around 30% of the U.S. retail wireless market. In addition, the firm provides wholesale service to resellers.
Read more on TMUS →